A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety of escalating multiple doses
over 2 weeks of CAT 1004 compared to placebo in patients with Type 2 diabetes (T2D).
Secondary objectives include evaluation of the pharmacokinetics (PK) and pharmacodynamics of
escalating multiple doses of CAT-1004 in patients with T2D.